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Percutaneous Treatment of Failed Native
Dialysis Fistulas: Use of Pulse-Spray
Pharmacomechanical Thrombolysis as
the Primary Mode of Therapy
Objective: To determine the efficacy and outcome of percutaneous treatment
in restoring the function of failed native arteriovenous fistulas (AVFs) where
pulse-spray pharmacomechanical thrombolysis was used as the primary mode of
therapy.
Materials and Methods: From June 2001 to July 2005, 14 patients who had
thrombosis of native AVFs underwent percutaneous restoration following 20
episodes of thrombosis. These included 6 repeated episodes in one forearm AVF
and two episodes in another forearm AVF. All patients except one were treated
with urokinase injection utilizing the pulse-spray technique and had subsequent
balloon angioplasty. One patient was treated by percutaneous angioplasty alone.
We retrospectively evaluated the feasibility of percutaneous treatment in restoring
the function of the failed AVFs. The primary and secondary patencies were calcu-
lated by using a Kaplan-Meier analysis. 
Results: Both technical and clinical success were achieved in 15 (75%) of 20
AVFs. Four of the five technical failures resulted from a failure to cross the
occluded segment. One patient refused further participation in the trial through a
brachial artery access following failure to cross the occluded segment via an ini-
tial retrograde venous puncture. There were no major precedure related compli-
cations observed. Including the initial technical failures, primary patency rates at
six and 12 months were 64% and 55%, respectively. Secondary patency rates at
six and 12 months were 71% and 63%, respectively.
Conclusion: Pulse-spray pharmacomechanical thrombolysis for treatment of
the thrombosed AVFs is safe, effective and durable. This procedure should be
considered as an option for the management of failed AVFs prior to surgical inter-
vention.
emodialysis patients require a functioning vascular access to achieve
long-term survival and an optimal quality of life. Depending on  age
when kidney failure occurs, between 23% and 51% of patients will live
at least an additional 10 years after starting dialysis (1). Because the number of
vascular access sites is limited, the preservation of each site for as long as possible is
important for the long-term management of these patients.
Arteriovenous fistulas (AVFs) have several advantages over synthetic grafts includ-
ing: better patency, fewer infections, lower incidence of vascular steal syndrome, and
reduced morbidity related to the surgical procedure during shunt creation (2). The
clinical practice guidelines of the National Kidney Foundation Dialysis Outcomes
Quality Initiative (NKF-DOQI) has recently recommended that, ultimately, 40% of
patients undergoing hemodialysis should have an arteriovenous fistula (3). However, it
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His also known that although the thrombosis rate for AVFs
has been reported to be approximately one sixth that for
synthetic grafts (4), a majority of autogenous fistulas
eventually fail; this contributes significantly to morbidity
and hospitalization for these patients. 
Traditionally, the standard therapy for a thrombosed
AVF has been surgical repair. Surgical thrombectomy with
repair of the underlying stenosis or creation of a new more
proximal arteriovenous anastomosis are procedures
commonly performed (5). However, the results of surgical
thrombectomy and revision are not satisfactory, with
reported success rates varying from 28% to 73% (6 8).
Because only a minority of thrombosed AVFs can be
salvaged surgically following a thrombosis (9), many
surgeons have recommended that salvage procedures
should not be attempted on thrombosed AVFs. Therefore,
additional management options are needed.
Recent studies suggest that percutaneous treatment is
effective in for salvaging thrombosed native AVFs (10
19). There are a variety of percutaneous methods available
to remove the clot formation from the fistulas. Current
approaches include: mechanical thrombectomy with
various devices, manual thromboaspiration, balloon
maceration of the clot, bolus or pulse-spray infusion of
thrombolytic agents, or a combination of any of these
methods. Reported technical success rates range from 73%
to 100% and primary and secondary patency rates at 6
months were 18% 81% and 44% 84%, respectively
(10 19).
We present here our experience with percutaneous
treatment in restoring the function of failed AVFs, in which
pulse-spray pharmacomechanical thrombolysis was used as
the primary mode of therapy, and report on the efficacy,
safety and durability.
MATERIALS AND METHODS
From June 2001 to July 2005, fourteen patients with
thrombosed native AVFs who underwent percutaneous
restoration for 20 episodes of thrombosis were included.
One patient experienced six episodes of thrombosis in a
forearm AVF and another patient experienced two
episodes of thrombosis in a forearm AVF. The included
patients were 10 men and four women who ranged in age
from 27 to 73 years with a mean age of 53.8 years. The
etiologies of end-stage renal disease requiring hemodialysis
were diabetes mellitus (n = 7), chronic glomerulonephritis
(n = 2), Immunoglobulin A nephropathy (n = 1), Henoch-
Schonlein purpura (n = 1), Alport syndrome (n = 1),
polycystic kidney disease (n = 1), and hypertension (n = 1).
All fistulas were side-to-end AVFs with a distal forearm
radio-cephalic Brescia-Cimino fistula in 12 patients, a mid
arm radio-cephalic AVF in one patient and an upper arm
brachio-cephalic AVF in one patient. Fistula location was
on the left side in 10 patients and on the right side in four
patients. Fistula duration ranged from two to 57 months
with a mean of 25.9 months from the time of creation
(median, 27.5 months). All patients underwent elective
treatment within 72 hours of clotting. Before intervention,
written informed consent detailing the planned procedure
was obtained.
Salvage Procedures
Puncture sites were anesthetized with 2% lidocaine
hydrochloride. All punctures were made using a 22-guage
single-wall vascular access needle or a micropuncture set
(Cook, Bloomington, IN). The direction and site of the
initial puncture was determined by clinical examination
and/or ultrasound of the fistula. A tourniquet was applied
for passive vein congestion to facilitate venous puncture by
palpation. In 17 of 18 thrombosed forearm AVFs, initial
puncture was made in the outflow cephalic vein of the
fistula: seven retrograde venous punctures (Fig. 1), three
antegrade venous punctures, and seven both retro- and
ante-grade venous punctures. The seven initial retro- and
ante-grade venous punctures were made directly into the
occluded segment of the thrombosed AVF where a long
segmental occlusion from the anastomosis to the outflow
vein near the elbow was suspected. One thrombosed
forearm AVF was initially accessed by a brachial artery
puncture because the vein of the fistula was immature and
not punctured. One thrombosed upper arm AVF, where a
thrill was palpated on the venous limb close to the anasto-
mosis, was accessed by an antegrade venous puncture. One
thrombosed mid arm AVF, where a long segmental
occlusion from the anastomosis was suspected, was initially
accessed by a brachial artery puncture. After a 6 or 7 Fr
vascular sheath(s) was/were introduced in a retrograde, an
antegrade, or a criss-cross fashion, a 0.035-inch hydrophilic
wire (Terumo, Tokyo, Japan) was manipulated across the
occluded segment with passage of the wire into a radial
artery or downstream outflow vein. Three cases of
thrombosed forearm AVFs needed an additional puncture
of the brachial artery to cannulate the AV anastomosis
because the wire did not thread the occluded segment near
or at the anastomosis in a retrograde fashion. Two upper
or mid arm fistulas needed an additional retrograde venous
puncture; to treat a separate stenosis at the anastomosis in
one (Fig. 2) and to perform aspiration thrombectomy with
a 7Fr curved catheter for residual thrombus within an
aneurysmal venous segment in the other. After evaluating
the arterial inflow and venous outflow of the AVFs with
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or sheath, we treated all occluded fistulas, except one, by
pharmacomechanical thrombolysis. One fistula presenting
with less than 1 cm of occlusion in the cephalic vein close
to the anastomosis was treated by clot maceration by
percutaneous balloon angioplasty alone.
Pharmacomechanical thrombolysis was performed with
initial urokinase administration and subsequent clot
maceration using a balloon catheter (Bluemax, Boston
Scientific, Watertown, MA; Powerplex extreme, Cordis,
Miami, FL). After placement of a multi-side port infusion
catheter (Cook, Bloomington, IN) in the thrombosed
segment, 100,000 IU to 750,000 IU of urokinase (25,000
IU/mL in a normal saline solution) was administered using
the pulse-spray technique (forceful injections of 12,500 IU
of urokinase every 20 seconds with a 1-mL tuberculin
syringe). The dosage of urokinase was determined at the
discretion of the treating radiologist and was based primar-
ily on the length of the occlusion. Namely, 3,000 IU to
5,000 IU of heparin (70 IU/kg) was injected either
intravenously before thrombolysis or as a mixture with
urokinase. In the long segmental occlusions, an infusion
catheter was initially placed at the venous end of the
occluded segment and repositioned to the arterial end of
the occluded segment after thrombolysis of the venous
segment had been accomplished. In the five thrombosed
AVFs where initial or additional puncture of the brachial
artery was needed, pharmacomechanical thrombolysis and
subsequent balloon dilation were performed through the
brachial artery access.
Balloon angioplasty was performed to macerate residual
thrombi and treat all underlying stenoses. The size of the
balloon used was determined by the size of the adjacent
vein distal to the area to be dilated. Typically, lesions near
the AV anastomosis were dilated with 4 6 mm balloon
catheters. Lesions of the venous outflow of the fistula were
dilated with 6 10 mm balloon catheters. Under fluoro-
scopic control, the angioplasty balloon was routinely
inflated up to 20 atmospheres for about 2 minutes until the
balloon waist disappeared. Resistant stenoses were treated
by prolonged balloon inflation for 5 10 minutes, up to 25
atmospheres or by using a balloon with a 1-mm larger
diameter. If necessary, the procedure was repeated until
the control angiogram revealed a satisfactory reduction in
residual stenosis. The acceptable degree of stenosis was less
than 30% of the adjacent vessel lumen. Two cases of
elastic recoils unresponsive to balloon inflation were
treated with a 5-mm cutting balloon (Boston Scientific,
Donegal, Ireland). No stents were placed.
After angioplasty, complete angiography was performed
from the arterial anastomosis to the right atrium. For
adherent or residual thrombi within the aneurysmal
venous segment persisting after initial urokinase injection
and subsequent balloon angioplasty, additional aspiration
thrombectomy with a 7 Fr curved guiding catheter
(Vistabrite tip guiding catheter, Cordis, Miami, FL) was
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Fig. 1. A. An angiogram of a forearm radio-cephalic arteriovenous fistula, obtained after passing a catheter into the radial artery (arrow)
via a retrograde venous access, shows a long segmental occlusion at the outflow cephalic vein (arrowheads).
B. Following administration of 500,000 IU of urokinase (not shown), an unmasked stenosis at the outflow cephalic vein (arrow) is treated
with a 6-mm balloon.
C, D. Final angiograms after the procedure show a successful flow restoration of the arteriovenous fistula with less than 30% residual
stenosis at the outflow cephalic vein (arrows). The function of the arteriovenous fistula was maintained until kidney transplantation 39
months after the procedure.
CDperformed. After the procedure, the introducer sheaths
were kept for immediate hemodialysis.
Definition and Data Analysis
Technical success was defined as the restoration of flow
in the fistula with a residual stenosis of less than 30%
diameter. Clinical success was defined as the resumption of
normal dialysis for at least one session after percutaneous
treatment. Complications were classified as major or minor
according to the criteria of the Society of Cardiovascular
and Interventional Radiology published guidelines (20).
Minor complications were defined as problems requiring
no or nominal therapy and having no clinical
consequences. Major complications were defined as
problems that required additional therapy with clinical
consequences. Primary patency was defined as the interval
following intervention until the next access thrombosis or
repeated intervention. Secondary patency was defined as
the interval after intervention until the access was
surgically declotted, revised, or abandoned.
Medical records and hemodialysis charts were reviewed
to obtain information for follow-up and access site compli-
cations. Follow-up information for four patients who had
dialysis performed in other hospitals, at the time of this
investigation, was obtained by telephone. The feasibility of
our technique was assessed by a retrospective analysis.
Primary and secondary patencies were calculated by using
a Kaplan-Meier analysis. 
RESULTS
Salvage of the thrombosed AVFs with flow restoration
was achieved in 15 (75%) of the 20 episodes in 10 (71%)
of 14 patients. Immediate hemodialysis after the
procedures resumed in all 15 cases that achieved technical
success. The function of one fistula was restored by balloon
angioplasty alone, that of 11 fistulas was restored by initial
urokinase injection and subsequent balloon angioplasty,
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Fig. 2. A. An angiogram of an upper arm brachio-cephalic arteri-
ovenous fistula, obtained after an antegrade puncture of the
cephalic vein close to the arteriovenous anastomosis, shows an
occlusion ending at the outflow cephalic vein (arrow) a few
centimeters away from the anastomosis. A focal severe stenosis is
also noted at the anastomosis (arrowhead).
B. Following administration of 300,000 IU of urokinase (not
shown), an unmasked stenosis at the outflow vein (arrow) is
treated with a 6-mm balloon.
C. Via an additional retrograde venous access, the focal stenosis
at the anastomosis is treated with a 5-mm balloon (arrow).
D, E. Final angiograms after the procedure show a successful flow
restoration of the arteriovenous fistula. The function of the arteri-
ovenous fistula was maintained until the time of investigation two
months after the procedure.
CD
Eand that of three fistulas by initial urokinase injection and
subsequent balloon angioplasty and aspiration thrombec-
tomy. Technical failures occurred in five forearm fistulas.
Four failures were attributed to the inability of to crossing
the occluded segment even with the use of ante- and retro-
grade approaches. Two of these cases occurred in
immature AVFs never used for hemodialysis having fistula
ages of two and three months, respectively. One patient,
who had a short segmental occlusion at the anastomosis,
refused further participation in the trial through a brachial
artery access following failure to cross the occluded
segment through an initial retrograde venous puncture.
After balloon dilation, there was one episode of minor
venous rupture which immediately healed without any
treatment. No patient complained of clinical respiratory
distress during or immediately after the salvage procedure.
There were no major complications related to the
procedure.
Including the initial technical failures, primary patency
rates at six and 12 months were 64% and 55%, respec-
tively and secondary patency rates at six and 12 months
were 71% and 63%, respectively (Fig. 3). The length of
follow-up ranged from two to 45 months (mean, 19.3
months; median, 11 months). Early re-thrombosis was seen
the next day after pharmacomechanical thrombolysis in
one forearm AVF which re-occluded four more times
during 11 months of follow-up. At all episodes, the
function of the AVF was successfully restored by percuta-
neous pharmacomechanical thrombolysis. Another
forearm AVF was re-thrombosed at a 10 month follow-up.
However, it could not be salvaged by percutaneous
treatment because a tight occlusion prohibited the guide
wire from passing. One patient died of pneumonia at 45
months after the procedure and another patient underwent
kidney transplantation at 39 months after the procedure.
DISCUSSION
Currently, purely mechanical and pharmacomechanical
thrombolysis are the two mainstays of percutaneous
treatment for thrombosed dialysis fistulas and grafts. Based
on the results for treating the thrombosed dialysis grafts,
the procedure times of mechanical thrombectomy were
shorter than those of pharmacomechanical thrombectomy,
but there were no significant differences in the technical
success, complication, and primary patency rates between
two groups (21 23). On the other hand, devices for
mechanical thrombectomy, except for balloon angioplasty
and manual thromboaspiration, are more expensive and
have the potential to damage the vein wall (23, 24).
Although it is still unclear which method is better, the
administration of a lytic agent, such as urokinase, has been
shown to reduce the clot burden in the fistula. In addition,
lytic agents address both small pulmonary emboli which
may be dislodged by mechanical maceration and pre-
existing pulmonary emboli (25).
The present study used pulse-spray pharmacomechanical
thrombolysis as the primary mode of therapy for the
percutaneous treatment of thrombosed native fistulas. A
technical success rate of 75% (15 of 20) was achieved with
primary and secondary patency rates of 64% and 71% at
six months and 55% and 63% at 12 months, respectively.
Published studies using mechanical thrombectomy as the
primary therapeutic method for removing clots in
thrombosed AVFs utilize various mechanical thrombec-
tomy devices, manual thromboaspiration, and balloon
maceration of clot (12 16, 18). These studies have
reported technical success rates of 76% 100% with
primary patency rates of 18% 81% at six months and
assisted primary or secondary patency rates of 60% 80%
at six months. Pharmacomechanical thrombolysis as a
primary therapeutic method for removing clots in
thrombosed AVFs has not been thoroughly investigated.
Schon and Mishler (17), in a study of 16 thrombosed
AVFs, used pharmacomechanical thrombolysis with a
bolus injection of low dose urokinase or tissue plasminogen
activator (tPA) in conjunction with external manual
maceration of clots; the reported technical success rate was
94%. Patency rates were not reported. In another study by
Zaleski et al. (10), initial anastomotic angioplasty, bolus
urokinase infusion for 1 minute, and balloon maceration of
the clot were used for pharmacomechanical thrombolysis
in 17 thrombosed fistulas. They reported a technical
success rate of 82% with primary patency rates of 71% at
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Fig. 3. A graph shows primary and secondary patency rates of
the thrombosed arteriovenous fistulas after percutaneous
treatment using pharmacomechanical thrombolysis as the
primary mode of therapy.six months and 64% at 12 months and secondary rates of
100% at six and 12 months (excluding initial failures).
Rajan et al. (19) used a method of pharmacomechanical
thrombolysis similar to ours; they treated 25 thrombosed
AVFs by pulse-spray injection of urokinase or recombinant
tPA in conjunction with balloon maceration or a thrombec-
tomy device to treat the clot, and reported a technical
success rate of 77% with primary and secondary patency
rates of 28% and 44% at six months and 24% and 44% at
12 months, respectively. 
Our study has a slightly lower technical success rate
compared to that of previous studies (10 19). Of our five
technical failures, one resulted from the patient’s refusal
and two failures developed in immature fistulas which
were not included in the previous studies. Thus, if these
three technical failures are excluded, our technical success
rate becomes 88% and is comparable to prior reports. The
primary and secondary patency rates of this study are
better when compared to those of Rajan et al. (19) who
used a technique similar to ours.
As in previous studies for thrombosed AVFs, the techni-
cal failures in this study are attributed primarily to the
inability to cross the occluded segment. Once this problem
could be overcome, percutaneous restoration was success-
ful in all 15 cases. In addition, if we exclude the five techni-
cal failures, primary and secondary patency rates are
excellent; 90% and 100% at six months and 77% and
88% at 12 months, respectively.
Thrombosed native AVFs have several features that
make them difficult to work with these include: a thin
venous wall that is difficult to palpate and is usually
transfixed without resistance, an irregular anatomy that
makes it frequently impossible to localize the anastomosis
clinically, an underlying stenosis that occurs anywhere
from the feeding artery to the central veins and is
frequently very tight and difficult to traverse, deceptive
collaterals, a great variety in clot volume, and more
frequent aneurysms than in synthetic grafts that usually
contain thick layers of old wall-adherent thrombi (12).
Therefore, percutaneous removal of clots is more difficult
to perform in standard native fistulas than synthetic grafts.
Despite this difficulty, the present study, as well as others,
show comparable technical success rates and much higher
primary patency rates than those (technical success rate,
85%; primary patency rates, 40% at 3 months)
recommended in the NKF-DOQI guidelines for dialysis
graft thrombolysis (3). Because there are neither uniform
methods nor reporting standards for treating thrombosed
fistulas, a variety of approaches have been used in this and
previous studies. However, we believe that a variety of
methods are acceptable as long as they achieve effective,
safe and durable results in treating underlying stenosis and
removing all thrombus formation.
The more aneurysmal portions of the fistula are
somewhat resistant to thrombolysis simply because not all
of the clots in these segments are immediately exposed to
the lytic agents. For our three patients with residual
thrombus formation within the aneurysmal venous
segment, which did not respond to urokinase infusion and
conventional balloon angioplasty, we used a catheter-
directed thromboaspiration. Zaleski et al. (10) treated the
residual thrombus within the aneurysmal venous segment
in five fistulas by using a compliant occlusion balloon
catheter.
During an 11 month follow-up, one patient who had a
right forearm AVF has experienced long segmental
occlusion, on six occasions, due to severe stenosis of the
outflow vein near the elbow region. Successful salvage was
achieved each time. It was deemed important to maintain
the fistula as long as possible because he had a history of
left arm AVF not salvaged.
Reported procedure-related complications include
puncture site problems such as local hematoma and
subcutaneous pseudoaneurysm, venous rupture or dissec-
tion, arterial embolism, bleeding or hematoma at remote
site, and symptomatic pulmonary embolism (20, 26). Some
of these problems were followed with observation and
others required surgery. One minor venous rupture after
balloon dilation which immediately healed without any
treatment occurred in our study. There were no major
procedure related complications. There were no cases of
pulmonary embolism.
Percutaneous treatment has several advantages over
surgical treatment: dialysis can be resumed immediately
without the need for placement of a temporary access
catheter, thrombolysis/thrombectomy can be performed on
an outpatient basis, and future access sites are not compro-
mised. In the present study, percutaneous restoration was
performed on an outpatient basis in 18 of 20 cases and
during hospitalization in two cases, due to pneumonia in
one and scheduled bilateral nephrectomy for polycystic
kidney disease in the other.
The limitations of this study are the relatively small
sample size and an inherent selection bias due to retrospec-
tive data collection. A larger prospective randomized study
is needed to assess primary patency more accurately and to
establish definitely the most technically successful method.
In conclusion, percutaneous treatment that uses pulse-
spray pharmacomechanical thrombolysis as the primary
mode of therapy provides an acceptable technical success
rate and excellent access patency in the salvage of failed
AVFs, and exceeds the rates recommended by NKF-DOQI
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guidelines for thrombosed grafts. Thus, pulse-spray
pharmacomechanical thrombolysis should be considered as
an option to restore the function of failed AVF before a
surgical procedure.
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